Published: 18 July 2018
Author(s): Christian Folli, Chiara Casiraghi, Simon Braham, Angelo Rovellini, Valter Monzani
Issue: July 2018
Section: Letter to the Editor

Millions of people are treated with antithrombotic drugs and major hemorrhages are the most threatening consequence. When this study was performed the prevalence in the general population of people treated with vitamin K-antagonists (VKA) was approximately 1%, and major hemorrhagic events occurred in 2–3% of patients treated with VKA [1-3]. The mortality of intracranial hemorrhage (ICH) occurring on anticoagulant treatment is 30–55%, with a very high morbidity in surviving patients [1-3]. When bleeding occurs, treatment to reverse anticoagulation should be started as soon as possible.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.